ReviewInternational journal of molecular sciences2021
Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 72 citations in OpenAlex.
- Beyond Acute Infection: A Conceptual Framework Linking Zoonotic Bacterial Pathogens to Pulmonary Fibrosis and Lung Carcinogenesis.Biomedicines · 2026Review
- Diffuse Alveolar Hemorrhage Following Trauma: A Diagnostic Dilemma With Rapid Steroid Response.Cureus · 2026Article
- The Role of Macrophage M1/M2 Polarization Imbalance in the Pathogenesis of Immune Associated Diffuse Alveolar Hemorrhage: Evidence From the Study of Human Clinical Specimens.Pediatric pulmonology · 2026Article
- Rare Models: Use of a Novel Translational Model for Diffuse Alveolar Haemorrhage.International journal of molecular sciences · 2026Review
- Bronchoscopy-Guided Bronchial Blocker for Acute Right Pulmonary Artery Hemorrhage in an Infant With Berry Syndrome: A Case Report.The American journal of case reports · 2026Article
- Clinical, radiological and laboratory features and outcomes of diffuse alveolar hemorrhage.Scientific reports · 2026Article
- Diffuse alveolar hemorrhage in rheumatic diseases: Clinical features, diagnosis, and management.Rheumatology and immunology research · 2026Article
- Cannabis-Induced Diffuse Alveolar Haemorrhage: A Case Report From the Intensive Care Unit.Cureus · 2026Article
- Diffuse Alveolar Hemorrhage as the Initial Manifestation of Acute Myelomonocytic Leukemia.Case reports in hematology · 2026Article
- Emergency in pediatric rheumatology: a narrative review.Frontiers in medicine · 2026Review
- Local Intrapulmonary Hemostatic Therapies for Pediatric Pulmonary Hemorrhage: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- [Clinical characteristics and prognosis of primary immune thrombocytopenia complicated with diffuse alveolar hemorrhage].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Respiratory infection induced episode of alveolar hemorrhage (RIIEAH) in the pediatric diffuse alveolar hemorrhage: a retrospective single-center study.BMC pediatrics · 2025Article
- Article
- Idiopathic pulmonary haemosiderosis in childhood.BMJ case reports · 2025Article
- Diffuse Alveolar Hemorrhage as the First Presentation of Systemic Lupus Erythematosus: A Case Report.The American journal of case reports · 2025Article
- Connective Tissue Disorder-Induced Diffuse Alveolar Hemorrhage: A Comprehensive Review with an Emphasis on Airway and Respiratory Management.Life (Basel, Switzerland) · 2025Review
- Microscopic polyangiitis with severe anemia as the first clinical manifestation.World journal of emergency medicine · 2025Article
- Management of severe acute pulmonary haemorrhage in children.The Lancet. Child & adolescent health · 2025Review
- Oxaliplatin-induced diffuse alveolar hemorrhage: A case report.World journal of clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or systemic autoimmune disorders. Pathologic findings show pulmonary capillaritis, bland hemorrhage, diffuse alveolar damage, and hemosiderin-laden macrophages, but in the majority of cases, pathogenesis remains unclear. Despite the severity and high mortality, the current treatment options for DAH remain empirical. Systemic treatment to control inflammatory activity including high-dose corticosteroids, cyclophosphamide, and rituximab and supportive care have been applied, but largely unsuccessful in critical cases. Activated recombinant factor VII (FVIIa) can achieve rapid local hemostasis and has been administered either systemically or intrapulmonary for the treatment of DAH. However, there is no randomized controlled study to evaluate the efficacy and safety, and the use of FVIIa for DAH remains open to debate. This review discusses the pathogenesis, diverse etiologies causing DAH, diagnosis, and treatments focusing on hemostasis using FVIIa. In addition, the risks and benefits of the off-label use of FVIIa in pediatric patients will be discussed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.